Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Jul 24, 2012

What the Top 10 Biopharma CEOs Are Making

GEN shows you who's in the money.

What the Top 10 Biopharma CEOs Are Making

These biotech leaders are the ones bringing home the most bacon. [© Mariusz Prusaczyk - Fotolia.com]

  • #10. Merck & Co.

    Kenneth C. Frazier, Chairman, President, and CEO

    2011 Compensation: $13,347,652

    2010 Compensation: $9,439,632

    % Change: 41.1%

  • #9. Baxter International

    Robert L. Parkinson Jr., Chairman and CEO

    2011 Compensation: $14,065,479

    2010 Compensation: $11,500,268

    % Change: 22.3%

  • #8. Bristol-Myers Squibb

    Lamberto Andreotti, CEO

    2011 Compensation: $14,911,947

    2010 Compensation: $11,770,880

    % Change: 26.7%

  • #7. Gilead Sciences

    John C. Martin, Chairman and CEO

    2011 Compensation: $15,615,645

    2010 Compensation: $14,244,388

    % Change: 9.6%

  • #6. Novartis

    Joseph Jimenez, CEO

    2011 Compensation1: $15,881,621

    2010 Compensation1: $11,828,828

    % Change: 34.3%



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »